Core Insights - Appili Therapeutics is actively participating in the BARDA Innovation Symposium to strengthen partnerships with U.S. federal agencies and advance medical countermeasures for public health emergencies [1][2] - The company has secured a contract worth up to US $40 million from NIAID for the development of the VXV-01 fungal vaccine candidate, highlighting its capabilities in infectious disease and biodefense innovation [2][7] - Appili has submitted multiple funding proposals totaling US $94 million to U.S. federal agencies, aiming to leverage public funding for high-priority anti-infective programs [7] Government Partnerships - Government partnerships are central to Appili's mission and business model, with significant contracts and collaborations enhancing its pipeline [2][3] - The company has secured over US $66 million in government contracts and grants, providing essential non-dilutive capital to accelerate its pipeline progress [7] BARDA and Innovation Symposium - The BARDA Innovation Symposium is a platform for showcasing early-stage health security innovations and fostering collaboration among diverse stakeholders in the medical countermeasures space [5][4] - BARDA, part of the U.S. Department of Health and Human Services, plays a crucial role in funding the development of medical countermeasures against various threats, including pandemics and emerging infectious diseases [4]